Corbus Pharmaceuticals Holdings Inc
CRBP
Company Profile
Business description
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Contact
500 River Ridge Drive
NorwoodMA02062
USAT: +1 617 963-0100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
28
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,741.90 | 26.70 | -0.30% |
| CAC 40 | 7,804.87 | 14.60 | 0.19% |
| DAX 40 | 24,304.46 | 19.12 | -0.08% |
| Dow JONES (US) | 42,762.87 | 443.13 | 1.05% |
| FTSE 100 | 8,837.91 | 26.87 | 0.30% |
| HKSE | 24,092.21 | 299.67 | 1.26% |
| NASDAQ | 19,529.95 | 231.51 | 1.20% |
| Nikkei 225 | 38,137.09 | 395.48 | 1.05% |
| NZX 50 Index | 12,529.42 | 34.06 | -0.27% |
| S&P 500 | 6,000.36 | 61.06 | 1.03% |
| S&P/ASX 200 | 8,515.70 | 23.20 | -0.27% |
| SSE Composite Index | 3,396.59 | 11.24 | 0.33% |